Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations (2024)

van der Pol, S., Zeevat, F., Postma, M. J. (2024). Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations. Vaccine, 42(15), 3429-3436. https://doi.org/10.1016/j.vaccine.2024.04.040

van der Pol, Simon ; Zeevat, Florian ; Postma, Maarten J et al. / Cost-effectiveness of high-dose influenza vaccination in the Netherlands : Incorporating the impact on both respiratory and cardiovascular hospitalizations. In: Vaccine. 2024 ; Vol. 42, No. 15. pp. 3429-3436.

@article{3a6767db66a34de29427e651d1efdee1,

title = "Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations",

abstract = "OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.RESULTS: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.CONCLUSIONS: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.",

author = "{van der Pol}, Simon and Florian Zeevat and Postma, {Maarten J} and Cornelis Boersma",

note = "Copyright {\textcopyright} 2024. Published by Elsevier India Pvt Ltd.",

year = "2024",

month = may,

day = "31",

doi = "10.1016/j.vaccine.2024.04.040",

language = "English",

volume = "42",

pages = "3429--3436",

journal = "Vaccine",

issn = "0264-410X",

publisher = "ELSEVIER SCI LTD",

number = "15",

}

van der Pol, S, Zeevat, F, Postma, MJ 2024, 'Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations', Vaccine, vol. 42, no. 15, pp. 3429-3436. https://doi.org/10.1016/j.vaccine.2024.04.040

Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations. / van der Pol, Simon; Zeevat, Florian; Postma, Maarten J et al.
In: Vaccine, Vol. 42, No. 15, 31.05.2024, p. 3429-3436.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cost-effectiveness of high-dose influenza vaccination in the Netherlands

T2 - Incorporating the impact on both respiratory and cardiovascular hospitalizations

AU - van der Pol, Simon

AU - Zeevat, Florian

AU - Postma, Maarten J

AU - Boersma, Cornelis

N1 - Copyright © 2024. Published by Elsevier India Pvt Ltd.

PY - 2024/5/31

Y1 - 2024/5/31

N2 - OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.RESULTS: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.CONCLUSIONS: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.

AB - OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.RESULTS: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.CONCLUSIONS: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.

U2 - 10.1016/j.vaccine.2024.04.040

DO - 10.1016/j.vaccine.2024.04.040

M3 - Article

C2 - 38631948

SN - 0264-410X

VL - 42

SP - 3429

EP - 3436

JO - Vaccine

JF - Vaccine

IS - 15

ER -

van der Pol S, Zeevat F, Postma MJ, Boersma C. Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations. Vaccine. 2024 May 31;42(15):3429-3436. Epub 2024 Apr 17. doi: 10.1016/j.vaccine.2024.04.040